MedTrace Logo

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

NCT00726037 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-09-29

Study results available
· View outcomes & findings →

Summary

This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.

Conditions

Interventions

DRUG

Ontak

One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day

Sponsors & Collaborators

  • Riveria Country Club Organization

    collaborator UNKNOWN

  • Eisai Inc.

    collaborator INDUSTRY

  • Loyola University

    lead OTHER

Principal Investigators

  • Margo Shoup, MD · Loyola University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00726037 on ClinicalTrials.gov